OncoAlert and ecancer weekly round up for February 7th - 13th, 2022

Update on the new EUSOMA quality indicators for breast cancer

The optimal approach after neoadjuvant treatment: The Lucerne toolbox

Tumour agnostic treatments in GI cancer

Neoadjuvant pembro + chemo vs placebo + chemo, followed by adjuvant pembro vs placebo for early-stage TNBC

Durvalumab plus chemotherapy significantly improved OS in advanced biliary tract cancer

Early treatment discontinuation and early oxaliplatin discontinuation for stage III colorectal cancer

HIMALAYA: Study of tremelimumab and durvalumab as first-line therapy in patients with uHCC

Comparing two chemo regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced oesophageal cancer

Nivo + chemo vs chemo as first-line treatment for advanced GC/GEJC/EAC

OncoAlert Colloquium Day 6: Gynaecological oncology, IGCS and ESO

OncoAlert Colloquium Day 5: SWOG, OncoAlliance and more